Efficacy and safety of once-monthly risedronate in osteoporosis subjects with mild-to-moderate chronic kidney disease: a post hoc subgroup analysis of a phase III trial in Japan

  • Toshitsugu Sugimoto
  • Daisuke InoueEmail author
  • Masayuki Maehara
  • Ichiro Oikawa
  • Takashi Shigematsu
  • Yoshiki Nishizawa
Original Article


Limited data are available on the safety and efficacy of anti-resorptive agents, particularly once-monthly bisphosphonates, for use in osteoporotic patients with chronic kidney disease (CKD). We conducted a post hoc analysis of data from a 12-month, randomized, double-blind, phase III study to evaluate the safety and efficacy of once-monthly risedronate (RIS-OM) 75 mg tablets in Japanese osteoporosis patients with mild-to-moderate CKD. Patients who received RIS-OM 75 mg were stratified by baseline estimated glomerular filtration rate (eGFR; ≥ 90, ≥ 60 to < 90, or ≥ 30 to < 60 mL/min/1.73 m2). Safety endpoints were incidence of adverse events (AEs) and percent change from baseline in eGFR, serum creatinine, calcium, and phosphorus. Efficacy endpoints were percent change from baseline in lumbar spine bone mineral density (BMD) and bone turnover markers (BTMs). In 420 patients included (age 67.7 ± 6.7 years, women 98.8%), the incidence of all AEs, gastrointestinal disorders, acute phase reaction, non-vertebral fractures, and renal and urinary disorders was not significantly different among subgroups. Interaction between subgroups and time was significant for eGFR (p = 0.010) and serum creatinine (p = 0.001) but considered to be regression to the mean and clinically insignificant. BMD significantly increased while BTMs significantly decreased from baseline with a similar degree of change among the subgroups. In conclusion, RIS-OM 75 mg showed consistent safety and efficacy in suppressing bone turnover and increasing BMD in Japanese primary osteoporosis patients with mild-to-moderate CKD. These results should, however, be interpreted with caution because the number of patients with moderate CKD was limited.


Bisphosphonate Chronic kidney disease eGFR Once-monthly risedronate Renal safety 



This study was supported by the Joint Development Program of EA Pharma Co., Ltd. and Takeda Pharmaceutical Co., Ltd. Medical writing services were provided by Mami Hirano, MS, of Cactus Communications, and funded by EA Pharma Co., Ltd. Support for statistical analysis was provided by Ryoichi Muraoka, DVM, of Asklep, and funded by EA Pharma Co., Ltd.

Author contributions

TSu, DI (guarantor), TSh, and YN designed the study. MM designed the study and contributed to the conduct of the study and data acquisition and interpretation. IO was responsible for statistical analysis and data interpretation. All authors critically reviewed the paper for intellectual content and approved the final version. All authors agree to be accountable for the work and to ensure that any questions related to the accuracy and integrity of the paper will be investigated and properly resolved.

Compliance with ethical standards

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from all individual participants included in the study.

Conflict of interest

Dr. Toshitsugu Sugimoto has received research grants from Eli Lilly Japan, Taisho Toyama Pharmaceutical, Chugai Pharmaceutical, Daiichi-Sankyo Co., Astellas Pharma, and Eisai, as well as consulting fee from Asahi-Kasei Pharma Co. Dr. Daisuke Inoue reports personal fees from EA Pharma and grants from Astellas Pharma, Asahi-Kasei Pharma, Chugai Pharmaceutical, Daiichi-Sankyo Co., EA Pharma, Eli Lilly Japan, Eisai, Pfizer, Ono Pharmaceutical, Taisho Toyama Pharmaceutical, Takeda Pharmaceutical, and Teijin Pharma, outside the submitted work. Mr. Masayuki Maehara and Mr. Ichiro Oikawa are full-time employees of EA Pharma. Dr. Takashi Shigematsu has received consultant fees from EA pharma and Takeda pharmaceutical. Dr. Yoshiki Nishizawa has no conflicts of interest to disclose.

Supplementary material

774_2018_977_MOESM1_ESM.tif (2.5 mb)
Percent change from baseline in a eGFR, b serum creatinine, c serum calcium, d serum phosphorus in the overall population (mean ± SD). *Significantly (p < 0.05) different from baseline. Ca calcium, Cre creatinine, eGFR estimated glomerular filtration rate, P phosphorus, SD standard deviation (TIF 2571 KB)


  1. 1.
    Qaseem A, Forciea MA, McLean RM, Denberg TD (2017) Treatment of low bone density or osteoporosis to prevent fractures in men and women: a clinical practice guideline update from the American College of Physicians. Ann Intern Med 166:818–839CrossRefPubMedGoogle Scholar
  2. 2.
    Compston J, Cooper A, Cooper C, Gittoes N, Gregson C, Harvey N, Hope S, Kanis JA, McCloskey EV, Poole KES, Reid DM, Selby P, Thompson F, Thurston A, Vine N (2017) UK clinical guideline for the prevention and treatment of osteoporosis. Arch Osteoporos 12:43CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Japan Osteoporosis Society (2015) Guideline for prevention and treatment of osteoporosis (written in Japanese). Accessed 6 Nov 2017
  4. 4.
    Camacho PM, Petak SM, Binkley N, Clarke BL, Harris ST, Hurley DL, Kleerekoper M, Lewiecki EM, Miller PD, Narula HS, Pessah-Pollack R, Tangpricha V, Wimalawansa SJ, Watts NB (2016) American Association of Clinical Endocrinologists and American College of Endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis—2016. Endocr Pract 22:1–42CrossRefGoogle Scholar
  5. 5.
    Rossini M, Bianchi G, Di Munno O, Giannini S, Minisola S, Sinigaglia L, Adami S (2006) Determinants of adherence to osteoporosis treatment in clinical practice. Osteoporos Int 17:914–921CrossRefPubMedGoogle Scholar
  6. 6.
    Cook PF, Emiliozzi S, McCabe MM (2007) Telephone counseling to improve osteoporosis treatment adherence: an effectiveness study in community practice settings. Am J Med Qual 22:445–456CrossRefPubMedGoogle Scholar
  7. 7.
    Briesacher BA, Andrade SE, Harrold LR, Fouayzi H, Yood RA (2010) Adoption of once-monthly oral bisphosphonates and the impact on adherence. Am J Med 123:275–280CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Kishimoto H, Maehara M (2015) Compliance and persistence with daily, weekly, and monthly bisphosphonates for osteoporosis in Japan: analysis of data from the CISA. Arch Osteoporos 10:231CrossRefPubMedGoogle Scholar
  9. 9.
    Ohta H, Solanki J (2015) Incorporating bazedoxifene into the treatment paradigm for postmenopausal osteoporosis in Japan. Osteoporos Int 26:849–863CrossRefPubMedGoogle Scholar
  10. 10.
    Lima GA, Paranhos Neto Fde P, Pereira GR, Gomes CP, Farias ML (2014) Osteoporosis management in patient with renal function impairment. Arq Bras Endocrinol Metabol 58:530–539CrossRefPubMedGoogle Scholar
  11. 11.
    Nickolas TL, McMahon DJ, Shane E (2006) Relationship between moderate to severe kidney disease and hip fracture in the United States. J Am Soc Nephrol 17:3223–3232CrossRefPubMedGoogle Scholar
  12. 12.
    Japanese Society of Nephrology (2014) Evidence-based clinical practice guideline for CKD 2013. Clin Exp Nephrol 18:346–423CrossRefGoogle Scholar
  13. 13.
    Miller PD, Jamal SA, Evenepoel P, Eastell R, Boonen S (2013) Renal safety in patients treated with bisphosphonates for osteoporosis: a review. J Bone Miner Res 28:2049–2059CrossRefPubMedGoogle Scholar
  14. 14.
    Miller PD (2011) The kidney and bisphosphonates. Bone 49:77–81CrossRefPubMedGoogle Scholar
  15. 15.
    Bock O, Boerst H, Thomasius FE, Degner C, Stephan-Oelkers M, Valentine SM, Felsenberg D (2007) Common musculoskeletal adverse effects of oral treatment with once weekly alendronate and risedronate in patients with osteoporosis and ways for their prevention. J Musculoskelet Neuronal Interact 7:144–148PubMedGoogle Scholar
  16. 16.
    Reid IR, Gamble GD, Mesenbrink P, Lakatos P, Black DM (2010) Characterization of and risk factors for the acute-phase response after zoledronic acid. J Clin Endocrinol Metab 95:4380–4387CrossRefPubMedGoogle Scholar
  17. 17.
    Miller PD, McClung MR, Macovei L, Stakkestad JA, Luckey M, Bonvoisin B, Reginster JY, Recker RR, Hughes C, Lewiecki EM, Felsenberg D, Delmas PD, Kendler DL, Bolognese MA, Mairon N, Cooper C (2005) Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study. J Bone Miner Res 20:1315–1322CrossRefPubMedGoogle Scholar
  18. 18.
    Delmas PD, McClung MR, Zanchetta JR, Racewicz A, Roux C, Benhamou CL, Man Z, Eusebio RA, Beary JF, Burgio DE, Matzkin E, Boonen S (2008) Efficacy and safety of risedronate 150 mg once a month in the treatment of postmenopausal osteoporosis. Bone 42:36–42CrossRefPubMedGoogle Scholar
  19. 19.
    Hagino H, Kishimoto H, Ohishi H, Horii S, Nakamura T (2014) Efficacy, tolerability and safety of once-monthly administration of 75 mg risedronate in Japanese patients with involutional osteoporosis: a comparison with a 2.5 mg once-daily dosage regimen. Bone 59:44–52CrossRefPubMedGoogle Scholar
  20. 20.
    Wilson LM, Rebholz CM, Jirru E, Liu MC, Zhang A, Gayleard J, Chu Y, Robinson KA (2017) Benefits and harms of osteoporosis medications in patients with chronic kidney disease: a systematic review and meta-analysis. Ann Int Med 166:649–658CrossRefPubMedGoogle Scholar
  21. 21.
    Jamal SA, Bauer DC, Ensrud KE, Cauley JA, Hochberg M, Ishani A, Cummings SR (2007) Alendronate treatment in women with normal to severely impaired renal function: an analysis of the fracture intervention trial. J Bone Miner Res 22:503–508CrossRefPubMedGoogle Scholar
  22. 22.
    Miller PD, Roux C, Boonen S, Barton IP, Dunlap LE, Burgio DE (2005) Safety and efficacy of risedronate in patients with age-related reduced renal function as estimated by the Cockcroft and Gault method: a pooled analysis of nine clinical trials. J Bone Miner Res 20:2105–2115CrossRefPubMedGoogle Scholar
  23. 23.
    Shigematsu T, Muraoka R, Sugimoto T, Nishizawa Y (2017) Risedronate therapy in patients with mild-to-moderate chronic kidney disease with osteoporosis: post hoc analysis of data from the risedronate phase III clinical trials. BMC Nephrol 18:66CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Uyama Y, Shibata T, Nagai N, Hanaoka H, Toyoshima S, Mori K (2005) Successful bridging strategy based on ICH E5 guideline for drugs approved in Japan. Clin Pharmacol Ther 78:102–113CrossRefPubMedGoogle Scholar
  25. 25.
    Ogura Y, Gonsho A, Cyong JC, Orimo H (2004) Clinical trial of risedronate in Japanese volunteers: single and multiple oral dose studies. J Bone Miner Metab 22:111–119CrossRefPubMedGoogle Scholar
  26. 26.
    Orimo H, Hayashi Y, Fukunaga M, Sone T, Fujiwara S, Shiraki M, Kushida K, Miyamoto S, Soen S, Nishimura J, Oh-Hashi Y, Hosoi T, Gorai I, Tanaka H, Igai T, Kishimoto H (2001) Diagnostic criteria for primary osteoporosis: year 2000 revision. J Bone Miner Metab 19:331–337CrossRefPubMedGoogle Scholar
  27. 27.
    Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, Yamagata K, Tomino Y, Yokoyama H, Hishida A (2009) Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis 53:982–992CrossRefGoogle Scholar
  28. 28.
    KDIGO (2012) Clinical practice guideline for the evaluation and management of chronic kidney disease. Chapter 1: definition and classification of CKD. Kidney Int Suppl 3:19–62Google Scholar
  29. 29.
    Satterthwaite FE (1946) An approximate distribution of estimates of variance components. Biom Bull 2:110–114CrossRefGoogle Scholar
  30. 30.
    Mitchell DY, St Peter JV, Eusebio RA, Pallone KA, Kelly SC, Russell DA, Nesbitt JD, Thompson GA, Powell JH (2000) Effect of renal function on risedronate pharmacokinetics after a single oral dose. Br J Clin Pharmacol 49:215–222CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Bertoldo F, Pancheri S, Zenari S, Boldini S, Giovanazzi B, Zanatta M, Valenti MT, Dalle Carbonare L, Lo Cascio V (2010) Serum 25-hydroxyvitamin D levels modulate the acute-phase response associated with the first nitrogen-containing bisphosphonate infusion. J Bone Miner Res 25:447–454CrossRefPubMedGoogle Scholar
  32. 32.
    Barnett AG, van der Pols JC, Dobson AJ (2005) Regression to the mean: what it is and how to deal with it. Int J Epidemiol 34:215–220CrossRefPubMedGoogle Scholar
  33. 33.
    Wheater G, Elshahaly M, Tuck SP, Datta HK, van Laar JM (2013) The clinical utility of bone marker measurements in osteoporosis. J Transl Med 11:201CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Yamada S, Inaba M, Kurajoh M, Shidara K, Imanishi Y, Ishimura E, Nishizawa Y (2008) Utility of serum tartrate-resistant acid phosphatase (TRACP5b) as a bone resorption marker in patients with chronic kidney disease: independence from renal dysfunction. Clin Endocrinol 69:189–196CrossRefGoogle Scholar
  35. 35.
    Fahrleitner-Pammer A, Herberth J, Browning SR, Obermayer-Pietsch B, Wirnsberger G, Holzer H, Dobnig H, Malluche HH (2008) Bone markers predict cardiovascular events in chronic kidney disease. J Bone Miner Res 23:1850–1858CrossRefPubMedGoogle Scholar
  36. 36.
    Imai E, Horio M, Watanabe T, Iseki K, Yamagata K, Hara S, Ura N, Kiyohara Y, Moriyama T, Ando Y, Fujimoto S, Konta T, Yokoyama H, Makino H, Hishida A, Matsuo S (2009) Prevalence of chronic kidney disease in the Japanese general population. Clin Exp Nephrol 13:621–630CrossRefPubMedGoogle Scholar

Copyright information

© The Japanese Society for Bone and Mineral Research and Springer Japan KK, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Internal Medicine, 1Shimane University Faculty of MedicineIzumoJapan
  2. 2.Third Department of MedicineTeikyo University Chiba Medical CenterChibaJapan
  3. 3.EA Pharma Co., Ltd.TokyoJapan
  4. 4.Department of NephrologyWakayama Medical UniversityWakayamaJapan
  5. 5.Department of Metabolism, Endocrinology and Molecular MedicineOsaka City University Graduate School of MedicineOsakaJapan
  6. 6.Inoue HospitalOsakaJapan

Personalised recommendations